Randall Cummins

Randall Cummins serves as a key procurement lead within the W40M MRC0 West agency under the Department of the Army, responsible for securing critical medical readiness capabilities essential to operational field care. He manages a high-priority acquisition portfolio focused on in-vitro diagnostic substances, surgical instrumentation, sterilization systems, and blood management technologies that enable high-acuity medical support in austere environments. His work directly supports the agency’s mission of ensuring medical sovereignty through timely, reliable access to advanced diagnostic and therapeutic solutions, requiring deep technical understanding of clinical lab workflows and battlefield medical logistics. Cummins maintains enduring relationships with leading medical technology providers including Roche Diagnostics Corporation, Abbott Molecular Inc., Cardinal Health 414, LLC, Surgical Neuromonitoring Associates, Inc., and Premier Shockwave, Inc. These partnerships reflect a preference for established, FDA-regulated manufacturers with proven track records in military-grade compliance, supply chain resilience, and rapid deployment capabilities. His contracting approach prioritizes performance-based requirements and technical specifications aligned with DoD medical standards, fostering long-term vendor collaboration over transactional procurement. His contracting patterns show a strong preference for unrestricted competition, with 88.8% of awards issued without set-asides, reflecting the technical complexity and specialized nature of the procurements. Small business participation is modest but intentional, with total small business set-asides at 7.1% and targeted support for service-disabled veteran-owned small businesses at 2.0%. While socioeconomic set-asides are limited, they are strategically applied to qualified vendors capable of meeting stringent performance and regulatory requirements. Cummins’ primary focus lies in NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing), which accounts for over 44% of his portfolio, alongside analytical laboratory instrumentation (334516) and pharmaceutical preparation (325412). His expertise centers on procuring molecular diagnostics, point-of-care testing systems, and sterile surgical kits—technologies vital to rapid battlefield triage and infectious disease surveillance.